Skip to content

Study · Randomized controlled trial · n = 210 · 2016

3 results

Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.

Chen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF, Da Wang J, Ning QX

International journal of cardiology15 Dec 2015Cited by 35 (Europe PMC)

PMID26849684 (opens in a new tab)DOI10.1016/j.ijcard.2015.12.009 (opens in a new tab)PepBankPUB-26849684
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with STEMI undergoing PCI, the prevalence of no-reflow was significantly lower with liraglutide than with placebo (5% vs 15%).

    In plain wordsIn patients having a heart attack procedure, no-reflow was less common with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePrevalence of no-reflow after PCI
    Study

    n = 210

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    No-reflow prevalence
    5%
    liraglutide
    No-reflow prevalence
    15%
    placebo

    Source sentences

    Summary
    The primary end point, the prevalence of no-reflow, was significantly lower in the liraglutide group than in the control group (5% vs. 15%, P=0.01).
    1 context sentence
    Summary · context
    Of these, 210 patients were randomized 1:1 to receive either liraglutide or placebo 30 min before PCI (1.8 mg).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with STEMI undergoing PCI, serum high-sensitivity C-reactive protein at 6-hour reperfusion was significantly lower with liraglutide than with placebo.

    In plain wordsIn patients having a heart attack procedure, a blood marker of inflammation was lower 6 hours after reperfusion with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum hs-CRP at 6-hour reperfusion
    Study

    n = 210

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    hs-CRP
    0.87 mg/dL
    liraglutide
    hs-CRP
    0.96 mg/dL
    placebo

    Source sentences

    Summary
    There was a significant decrease in serum high-sensitivity C-reactive protein levels at 6-hour reperfusion in the liraglutide group compared to the control group (0.87 ± 0.09 mg/dL vs. 0.96 ± 0.10mg/dL, P<0.001).
    1 context sentence
    Summary · context
    Of these, 210 patients were randomized 1:1 to receive either liraglutide or placebo 30 min before PCI (1.8 mg).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with STEMI undergoing PCI, the incidence of major adverse cardiovascular events did not differ between liraglutide and placebo during 3 months of follow-up.

    In plain wordsIn patients having a heart attack procedure, heart events over 3 months were no different with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMajor adverse cardiovascular events at 3 months
    Study

    n = 210

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    During a 3-month follow-up period, no difference was observed in the incidence of major adverse cardiovascular event.
    1 context sentence
    Summary · context
    Of these, 210 patients were randomized 1:1 to receive either liraglutide or placebo 30 min before PCI (1.8 mg).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial pageClinicalTrials.govUpdated 12 Oct 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.